You just read:

Esperance Pharmaceuticals Presents Results From Phase 1 Study of EP-100 in Advanced, Refractory LHRH-Receptor Expressing Solid Tumors at ASCO

News provided by

Esperance Pharmaceuticals

Jun 04, 2012, 09:02 ET